Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 4
1998 9
1999 19
2000 6
2001 14
2002 8
2003 1
2004 5
2005 4
2006 6
2007 10
2008 5
2009 16
2010 13
2011 18
2012 14
2013 17
2014 33
2015 38
2016 29
2017 34
2018 35
2019 25
2020 43
2021 28
2022 28
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

446 results
Results by year
Filters applied: . Clear all
Page 1
Editorial: Candida biofilms.
Junqueira JC, Mylonakis E. Junqueira JC, et al. Among authors: mylonakis e. Front Microbiol. 2023 Jan 4;13:1128600. doi: 10.3389/fmicb.2022.1128600. eCollection 2022. Front Microbiol. 2023. PMID: 36687614 Free PMC article. No abstract available.
Babesiosis.
Filbin MR, Mylonakis EE, Callegari L, Legome E. Filbin MR, et al. Among authors: mylonakis ee. J Emerg Med. 2001 Jan;20(1):21-4. doi: 10.1016/s0736-4679(00)00289-4. J Emerg Med. 2001. PMID: 11165832 Review.
Effector triggered immunity.
Rajamuthiah R, Mylonakis E. Rajamuthiah R, et al. Among authors: mylonakis e. Virulence. 2014;5(7):697-702. doi: 10.4161/viru.29091. Virulence. 2014. PMID: 25513770 Free PMC article. Review.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. Baddley JW, et al. Among authors: mylonakis e. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Clin Microbiol Infect. 2018. PMID: 29459143 Free article. Review.
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
ACTIV-3/TICO Study Group; Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neaton JD, Lundgren JD. ACTIV-3/TICO Study Group, et al. Among authors: mylonakis e. Ann Intern Med. 2022 Sep;175(9):1266-1274. doi: 10.7326/M22-1503. Epub 2022 Aug 9. Ann Intern Med. 2022. PMID: 35939810 Free PMC article. Clinical Trial.
446 results